SanBio Company Limited (SNBIF)
SanBio Company Limited
St. Luke Tower
13th Floor 8-1 Akashi-cho Chuo-ku
Tokyo 104-0044
Japan
81 3 6264 3481
https://www.sanbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 29
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Toru Kawanishi | Co-Founder & Executive Chairman | N/D | N/D | 1967 |
| Mr. Keita Mori MBA | Co-Founder, President, Executive Officer, CEO & Representative Director | N/D | N/D | 1967 |
| Mr. Yoshihiro Kakutani | Corporate Officer of Management Administration | N/D | N/D | N/D |
| Mr. Greg Gillas | Senior Vice President of Human Resources & Corporate Services | N/D | N/D | N/D |
| Mr. Naoki Tsukahara | Senior Corporate Officer | N/D | N/D | N/D |
| Dr. Kazumi Sawaguchi Ph.D. | Corporate Officer and Head of Japan Regulatory Affairs & Quality Compliance Japan | N/D | N/D | N/D |
| Mr. Keizo Nakada | Corporate Officer & Head of Production | N/D | N/D | N/D |
| Shinya Hirata | Corporate Officer & Head of Research and Development | N/D | N/D | N/D |
| Mr. Dai Chida | Senior Scientific Advisor | N/D | N/D | N/D |
| Masumi Akahori | In charge of IR | N/D | N/D | N/D |
Descripción
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson's disease, spinal cord injury, and Alzheimer's disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
Gestión corporativa
La calificación ISS Governance QuickScore de SanBio Company Limited a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
